← Back to Clinical Trials
Recruiting NCT07168382

NCT07168382 AI-Based Personalized Health and Self-Care

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07168382
Status Recruiting
Phase
Sponsor Emre Sezgin
Condition Social Needs Status
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2026-04-24
Primary Completion 2028-08

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
DAPHNE Chatbot InterventionStandard HRSN Screening and Referral (Usual Care)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2026-04-24 with a primary completion date of 2028-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if the DAPHNE chatbot can improve caregiver engagement, usability, and integration of social care support tools into clinical workflows in caregivers of pediatric patients receiving care at the Nationwide Children's Hospital Primary Care Center (NCH PCC). This is a pilot randomized clinical trial. The main questions it aims to answer are: * Is the DAPHNE chatbot usable, acceptable, and minimally burdensome for caregivers over a 6-month period? * Can the DAPHNE chatbot be effectively integrated into primary care provider workflows? Researchers will compare the DAPHNE chatbot intervention arm to the standard of care control arm to see if the intervention improves caregiver-reported outcomes and provider workflow integration. Participants that are patients will be randomly assigned to either the DAPHNE chatbot group or the standard of care group. Complete surveys assessing usability, acceptability, and burden and participate in brief qualitative interviews to share feedback on their experience. Participants that are Primary Care providers will discuss integration of DAPHNE into clinical workflows and complete workflow integration assessments.

Eligibility Criteria

Inclusion Criteria (Caregivers): * Must be a caregiver of a child seen within the NCH primary care network who self-identifies with at least one unmet social need * Must be 18 years of age or older * Must be English-speaking * Must have a device that connects to the internet Inclusion Criteria (Primary Care Providers and Support Team Members): * Must be 18 years or older * Must be employed at Nationwide Children's Hospital Exclusion Criteria: \- Due to the intervention only being translated into English, non-English Speakers will be excluded from this study.

Contact & Investigator

Central Contact

Emre Sezgin, PhD

✉ Emre.Sezgin@nationwidechildrens.org

📞 (614) 722-3179

Principal Investigator

Emre Sezgin, PhD

PRINCIPAL INVESTIGATOR

Nationwide Children's Hospital

Frequently Asked Questions

Who can join the NCT07168382 clinical trial?

This trial is open to participants of all sexes, studying Social Needs Status. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07168382 currently recruiting?

Yes, NCT07168382 is actively recruiting participants. Contact the research team at Emre.Sezgin@nationwidechildrens.org for enrollment information.

Where is the NCT07168382 trial being conducted?

This trial is being conducted at Columbus, United States.

Who is sponsoring the NCT07168382 clinical trial?

NCT07168382 is sponsored by Emre Sezgin. The principal investigator is Emre Sezgin, PhD at Nationwide Children's Hospital. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology